U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07558863) titled 'Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes' on April 14.
Brief Summary: This study aims to investigate whether a class of diabetes medications called GLP-1 receptor agonists (GLP-1RA), specifically semaglutide or polyethylene glycol loxenatide, can improve heart-related nerve damage in people with type 2 diabetes. This heart-related nerve damage is known as diabetic cardiac autonomic neuropathy (DCAN), which can cause problems such as fast resting heart rate, low blood pressure upon standing, and in severe cases, heart attack or sudden death.
In this study, 60 adults with type 2 diabetes (ages 18-80) will be...